ITUS Corporation funds, develops, acquires, and licenses emerging technologies in the areas of biotechnology. The company, through its subsidiary, Anixa Diagnostics Corporation, is developing a platform called Cchek, a series of non-invasive, blood tests for the early detection of solid tumor based cancers. It has a collaboration agreement with The Wistar Institute for the development of Cchek. The company was formerly known as CopyTele, Inc. and changed its name to ITUS Corporation in September 2014. The company was founded in 1982 and is based in Los Angeles, California.
Report showed yesterday that it has successfully utilized its proprietary Cchekâ„¢ early cancer detection platform to identify the presence of Thyroid Cancer. http://www.allotcbb.com/quote.php?symbol=itus Technically speaking, MACD goes green, bullish cross in Stochastic oscillator and RSI is trading near to 76.474 level with positive bias. Next resistance watch: 6.49
Last two sessions have seen a massive move! ITUS Will Present Early Cancer Detection Data at ASCO-SITC Symposium on January 26